[Retracted] The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer
Table 2
The relationship between serum CYFRA21-1 and CEA and chemotherapeutic efficacy.
Variables
PD cases (%)
Crude
Model 1
Model 2
RR (95% CI)
RR (95% CI)
RR (95% CI)
CYFRA21-1 change rate
≤0
72
4 (5.6)
1.0 (1.0, 1.0)
Ref.
1.0 (1.0, 1.0)
Ref.
1.0 (1.0, 1.0)
Ref.
>0
31
7 (22.6)
5.0 (1.3, 18.4)
0.017
4.9 (1.3, 19.2)
0.022
3.0 (0.7, 12.8)
0.129
Per
2.6 (1.3, 5.2)
0.005
3.1 (1.4, 6.8)
0.005
2.1 (0.9, 4.5)
0.068
CEA change rate
≤0
57
1 (1.8)
1.0 (1.0, 1.0)
Ref.
1.0 (1.0, 1.0)
Ref.
1.0 (1.0, 1.0)
Ref.
>0
46
10 (21.7)
15.6 (1.9, 126.8)
0.010
16.5 (1.9, 142.3)
0.011
13.0 (1.4, 118.0)
0.023
Per
5.8 (2.3, 14.8)
<0.001
6.0 (2.2, 16.8)
0.001
5.5 (1.7, 17.5)
0.004
IQR: interquartile range; cases: the number of participants in processing; RR: relative risk; CI: confidence interval. Model 1: adjusted for age, ECOG PS score, gender, and primary tumor type by location. Model 2: model 1+CYFRA21-1 change rate+CEA change rate.
